Please login to the form below

Ultomiris

This page shows the latest Ultomiris news and features for those working in and with pharma, biotech and healthcare.

Alexion and NICE agree confidential discount for Ultomiris use on the NHS

NICE said clinical evidence shows Ultomiris is as effective and safe as Alexion's older PNH drug Soliris. ... Compared with Alexion’s older drug, Ultomiris is a cost-effective use of NHS resources, concluded NICE.

Latest news

Novartis receives FDA breakthrough therapy designation for rare disease med

Alexion’s other long-acting C5 inhibitor, Ultomiris (ravulizumab‑cwvz) is also approved in these indications, making the franchise Novartis potential main competitors.
AstraZeneca to acquire Alexion for $39bn

This includes the company’s complement component 5 (C5) inhibitors Soliris (eculizumab) and Ultomiris (ravulizumab), which are already available in the US and EU.
Apellis jumps as pegcetacoplan tops Alexion’s Soliris in PNH trial

with C5 inhibitor Soliris and Alexion’s follow-up Ultomiris (ravulizumab), which brought in $990m and $90m respectively in the third quarter of 2019. ... Alexion was quick to point out that the standard treatment for PNH is shifting from Soliris to
Alexion eyes Soliris combo with $930m deal to buy Achillion

Both Achillion’s drugs could be used in combination with Soliris as well as Alexion’s longer-acting follow-up drug Ultomiris (ravulizumab) in PNH – a life-threatening disorder in which
Amgen takes aim at Alexion’s patents for Soliris

PNH therapy Ultomiris (ravulizumab), which was granted an earlier than expected FDA approval last December. ... In trials, Ultomiris matched Soliris for efficacy – with a trend towards superiority – and offers improved dosing.

More from news
Approximately 1 fully matching, plus 8 partially matching documents found.

Latest Intelligence

Orphan drugs and breakthrough therapies drive Cortellis Drugs to Watch 2019

The forecast for 2023 sales is $1.97bn. Ultomiris (ravulizumab), from Alexion, treats paroxysmal nocturnal haemoglobinuria, a rare, potentially fatal blood disorder. ... Ultomiris received approval as an Orphan Drug from the FDA for adult patients with
Drug launches to watch in 2019

Analysts predict peak sales of up to $3bn. 5. Ultomiris – Alexion’s follow-up to Soliris. ... The follow-up, Ultomiris ALXN1210, is a second-generation PNH therapy with an NPV of $10.9bn.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

Freelance Account Manager - Creative Healthcare Comms - Immediat...: Excellent Day Rate

Freelance Medical Writer - Creative Healthcare Comms - 2 month t...: Excellent Day Rate

Senior Leadership Role – Medical Communications – North West: Highly Competitive Salary, Bonus &Benefits

Home Working Medical Copy Writer & Senior Medical Copy Write...: Highly Competitive Salary, Bonus &Benefits

Editor & Senior Editor - Medical Communications - Home Based: Highly Competitive Salary, Bonus &Benefits

Medical Writer, Senior Medical Writer, Principal Medical Writer,...: Highly Competitive Salary, Bonus &Benefits

Senior Account / Programme Manager - MedComms - Buckinghamshire: Highly Competitive Remuneration packages

Account Management: Competitive Salary Offered

Client Services Director – London or Home Based – Medical Commun...: Highly Competitive Salary, Bonus &Benefits

FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...: Highly Competitive Day Rate, Bonus &Benefits

Senior Account Director & Associate Director - Healthcare Ad...: Highly Competitive Salary, Bonus &Benefits

Senior Content Editor - Biotechnology: Salary TBC

PMHub

Add my company

COUCH Health

We are a patient engagement agency committed to making clinical study experiences human. By guiding organisations in making everything they...

Latest intelligence

InSite Events™ National Pharma Meeting: A Customer Story: How our client leveraged Impetus Digital’s white-glove service, 360° coverage and care, and award-winning InSite Events™ platform to successfully transfer their annual national meeting online....
Fear or encouragement, which is best to drive behaviour change?: The communications industry depends on fear of the perceived loss of something, in order to create the hope found in a product benefit. But, if if left too long unchecked,...
The unheard, unseen, and uncorrected effects of COVID-19: The disproportionate effects of the pandemic have been highlighted amongst ethnic minorities, so is it likely that ethnic minorities will be more worried about participating? And could this exacerbate inequalities...